Hostname: page-component-84b7d79bbc-fnpn6 Total loading time: 0 Render date: 2024-07-29T22:18:12.834Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey

Published online by Cambridge University Press:  07 November 2014

Donna Antonucci ,
Craig Kunins ,
Michael Manos ,
Frank A. López  and
Donna L. Kerney
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Lisdexamfetamine dimesylate (LDX) is a prodrug stimulant approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6–12 years of age. Parent surveys provide valuable information regarding the impact of ADHD treatments.

Methods:

Parents of children with ADHD beginning treatment with LDX voluntarily completed surveys through an automated telephone system or the Internet before and 6 weeks after LDX treatment initiation. Prescribing physicians received individual reports of the responses for each survey completed by their patients' parents. All patients whose parents completed both baseline and 6 week surveys were included in the analyses. Subgroup analyses were conducted for those previously treated with medications to treat ADHD, including mixed amphetamine salts-extended release.

Results:

LDX treatment was associated with a significant decrease in ADHD symptom interference with school activities, family interactions, homework, and social interactions (P<.01; N= 11,576). Parents rated satisfaction with LDX as significantly higher than with their child's previous treatment (P<.01). On average, global improvement, tolerability, convenience, and satisfaction with LDX were all highly rated.

Conclusion:

Patients treated with LDX showed significant symptom improvement and parents reported significantly greater satisfaction than with prior treatment.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 4 , April 2010 , pp. 248 - 256
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Biederman, J, Faraone, SV. Attention-deficit hyperactivity disorder. Lancet. 2005; 366: 237–248.CrossRefGoogle ScholarPubMed
2. Vyvanse® [package insert]. Wayne, PA: Shire US Inc. 2008.Google Scholar
3. Biederman, J, Boellner, SW, Childress, A, López, FA, Krishnan, S, Zhang, Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007; 62: 970–976.CrossRefGoogle ScholarPubMed
4. Ermer, J, Homolka, R, Martin, P, Buckwalter, M, Purkayastha, J, Roesch, BG. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers. Poster presented at: U.S. Psychiatric and Mental Health Congress, October 30-November 2, 2008; San Diego, CA.Google Scholar
5. Biederman, J, Krishnan, S, Zhang, Y, McGough, JJ, Findling, RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007; 29: 450–463.CrossRefGoogle ScholarPubMed
6. Wigal, SB, Kollins, SH, Squires, LA, Childress, AC. Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.Google Scholar
7. López, FA. ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr. 2006; 27: 410–416.CrossRefGoogle ScholarPubMed
8. Findling, R, Jain, R, Gao, J, Richards, C, Ginsberg, L. A dose-optimization study of the efficacy, safety, and tolerability of lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.Google Scholar
9. Schachter, HM, Pham, B, King, J, Langford, S, Moher, D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001; 165: 1475–1488.Google ScholarPubMed
10. Faraone, SV, Biederman, J, Roe, C. Comparative efficacy of Adderall and methlphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002; 22: 468–473.CrossRefGoogle Scholar
11. Biederman, J, Faraone, SV, Monuteaux, MC, Grossbard, JR. How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatements? A pooled analysis of parents' and teachers' reports. Pediatrics. 2004; 113: 1667–1671.CrossRefGoogle Scholar
12. Biederman, J, Gao, H, Rogers, AK, Spencer, TJ. Comparison of parent and teacher reports of attentions-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006; 60: 1106–1110.CrossRefGoogle ScholarPubMed
13. Sallee, FR, Ambrosini, PJ, López, FA, Shi, L, Michaels, MA; LADD.CAT Study Group. Health-related quality of life and treatment satisfaction and preference in a community assessment study of extended-release mixed amphetamine salts for children with attention-deficit/hyperactivity disorder J Outcomes Res. 2004; 8: 27–49.Google Scholar
14. Trattler, W, Katsev, D, Kerney, D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Clin Ther. 2006; 28: 1848–1856.CrossRefGoogle ScholarPubMed
15. Kerney, DL, Paradis, D, Brunton, S. Patient perceptions of insulin detemir as reported through patient telephone surveys. Curr Med Res Opin. 2007; 23: 2043–2049.CrossRefGoogle ScholarPubMed